Transaction DateRecipientSharesTypePriceValue
9th December 2020Matthew L Sherman207Exercise of derivative$34.43$7,127.01
1st December 2020Michael Douglas Taylor11,309Open or private sale$61.16$691,692.37
1st December 2020Michael Douglas Taylor1,011Open or private sale$61.87$62,546.83
1st December 2020Michael Douglas Taylor200Open or private sale$62.94$12,588.00
1st December 2020Michael Douglas Taylor19,000Exercise of derivative$1.89$35,910.00
1st December 2020Michael Douglas Taylor6,480Open or private sale$60.23$390,315.02
4th November 2020Michael Douglas Taylor15,000Exercise of derivative$1.89$28,350.00
4th November 2020Michael Douglas Taylor12,169Open or private sale$64.67$786,953.41
4th November 2020Michael Douglas Taylor2,831Open or private sale$65.36$185,033.59
2nd November 2020Michael Douglas Taylor23,315Exercise of derivative$1.89$44,065.35
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Deciphera Pharmaceuticals, Inc. develops and manufactures kinase inhibitor treatments for cancer. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.


Ticker: DCPH
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1654151
Employees: 258
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $155 M (29%)
Inventory, Net: $1 M (0%)
Assets, Current: $633 M (6%)
Property, Plant and Equipment, Net: $10 M (51%)
Assets: $686 M (10%)
Accounts Payable, Current: $13 M (-35%)
Liabilities, Current: $51 M (-14%)
Liabilities: $67 M (-12%)
Common Stock, Value, Issued: $561 Th (8%)
Common Stock, Shares, Issued: $56 M (8%)
Additional Paid in Capital, Common Stock: $1 B (20%)
Retained Earnings (Accumulated Deficit): $628 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $8 Th (-92%)
Stockholders' Equity (Parent): $620 M (0%)
Liabilities and Equity: $686 M (10%)
Revenue: $7 M (0%)
Cost of Revenue: $8 Th (0%)
Research and Development: $46 M (-52%)
Operating Income/Loss: $69 M (-52%)
Other Income, net: $2 M (-59%)